Kernicterus (jaundice) in newborns - Causes, Treatment & When to See a Doctor

```html

What is Kernicterus (jaundice) in newborns?

Kernicterus is a rare but serious form of brain damage that occurs when an extremely high level of bilirubin (a yellow pigment produced by the breakdown of red blood cells) builds up in a newborn’s blood and penetrates the blood‑brain barrier. In everyday language it is often referred to as “severe neonatal jaundice.” While ordinary newborn jaundice is common and usually harmless, kernicterus represents the toxic end of the spectrum and can cause permanent neurological impairment or death if not recognized and treated promptly.

Physiologically, newborns have a relatively immature liver that processes bilirubin less efficiently than an adult’s liver. When bilirubin levels exceed the liver’s capacity to conjugate and excrete it, the unconjugated (indirect) bilirubin circulates in the bloodstream. If the concentration rises above roughly 20–25 mg/dL (depending on gestational age), the pigment can cross into the central nervous system, depositing in structures such as the basal ganglia, hippocampus, and cerebellum—hence the name “kernicterus” (Greek “kernos” = kernel, referring to the brain’s gray‑matter nuclei).

Early detection and aggressive management of high bilirubin levels are crucial because the neurological damage caused by kernicterus is often irreversible.

Common Causes

Several conditions predispose a newborn to develop dangerously high bilirubin levels. Below are the most frequent contributors:

• Physiologic (normal) newborn jaundice: Peaks at 3–5 days of life; usually benign but can be exaggerated.
• Breast‑feeding jaundice: Inadequate intake leads to dehydration and reduced bilirubin clearance.
• Breast‑feeding milk jaundice: Certain substances in breast milk inhibit bilirubin conjugation (often resolves after 2–3 weeks).
• Hemolytic disease of the newborn (HDN): Maternal‑fetal blood group incompatibility (e.g., ABO or Rh).
• Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency: Enzyme defect causing increased red‑cell breakdown.
• Hereditary spherocytosis or other red‑cell membrane disorders: Accelerated hemolysis.
• Prematurity: Immature liver enzymes and lower albumin binding capacity.
• Crigler‑Najjar syndrome (type I & II): Rare genetic defects in bilirubin‑UDP‑glucuronosyltransferase.
• Sepsis or severe infection: Increases hemolysis and impairs hepatic function.
• Medication‑induced bilirubin elevation: Certain antibiotics (e.g., sulfonamides), anticonvulsants, or maternal drugs that displace bilirubin from albumin.

Associated Symptoms

When bilirubin levels climb, the newborn may display classic signs of jaundice, but as the level approaches the neurotoxic range, additional neurological manifestations can appear:

• Yellowing of the skin and sclera (eyes) – usually first noticeable on the face, then spreading to the chest, abdomen, and limbs.
• Lethargy or excessive sleepiness.
• Weak sucking or difficulty feeding.
• High‑pitched cry or “inconsolable” crying.
• Hypotonia (floppy or limp limbs).
• Arching of the back (opisthotonus) in severe cases.
• Seizures – may be focal or generalized.
• Movement disorders later in life (e.g., choreoathetoid movements) if kernicterus causes permanent brain injury.

When to See a Doctor

Newborn jaundice is common, but parents should act quickly if any of the following occur:

• Yellow discoloration that spreads to the chest, abdomen, or limbs.
• Jaundice that appears within the first 24 hours of life (early onset).
• Baby is unusually sleepy, difficult to arouse, or has a weak cry.
• Feeding problems – poor weight gain, infrequent feeds, or prolonged vomiting.
• Any sign of dehydration (dry mouth, no wet diapers for >6 hours).
• Seizures, stiff or floppy movements, or a fever above 100.4 °F (38 °C).

When in doubt, contact your pediatrician or go to the nearest emergency department. Early intervention can prevent progression to kernicterus.

Diagnosis

Healthcare providers use a combination of clinical assessment and laboratory tests to evaluate jaundice and the risk of kernicterus.

1. Physical examination: Careful inspection of skin and sclera for yellowing; assessment of hydration, tone, and feeding.
2. Transcutaneous bilirubinometer (TcB): Non‑invasive device that estimates bilirubin through the skin. Useful for screening.
3. Serum total bilirubin (TSB) measurement: Blood draw to obtain an accurate bilirubin level; differentiates direct (conjugated) from indirect (unconjugated) bilirubin.
4. Blood type and Coombs test: Detects maternal‑fetal blood group incompatibility.
5. Complete blood count (CBC) & reticulocyte count: Evaluates hemolysis.
6. G6PD screening: Especially in populations with higher prevalence.
7. Liver function tests (ALT, AST, PT/INR): Rule out hepatic causes.
8. Head ultrasound or MRI (rare): May be ordered if neurological signs suggest kernicterus.

Clinicians plot the TSB value on age‑specific nomograms (e.g., the “Bhutani nomogram”) to determine the need for phototherapy or exchange transfusion.

Treatment Options

The primary goal is to reduce bilirubin levels quickly enough to prevent it from crossing the blood‑brain barrier.

Phototherapy

• Standard of care for most newborns with elevated bilirubin.
• Blue‑green light (460‑490 nm) converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Types: conventional overhead lamps, fiber‑optic blankets, or LED blankets.
• Typical duration: 12–48 hours, depending on the rate of decline.

Exchange Transfusion

• Reserved for bilirubin levels >20‑25 mg/dL (or lower if the infant shows neurologic signs).
• Involves replacing the baby's blood with donor, washed red cells to rapidly lower bilirubin and remove antibodies.
• Performed in a neonatal intensive care unit (NICU) by a skilled team.

Intravenous Immunoglobulin (IVIG)

• Useful in hemolytic disease of the newborn (e.g., Rh incompatibility) to block further hemolysis.
• Can reduce the need for exchange transfusion.

Supportive Measures

• Frequent feeding (30 mL/kg/day) – promotes bilirubin excretion via stool and urine.
• Intravenous fluids if oral intake is inadequate.
• Monitoring of temperature, glucose, and electrolytes during intensive treatment.

Long‑Term Management (if kernicterus occurs)

• Neurodevelopmental therapy – physical, occupational, and speech therapy.
• Audiology follow‑up (hearing loss is common).
• Management of movement disorders with medications (e.g., baclofen, gabapentin).
• Regular developmental assessments to identify learning or behavioral issues early.

Prevention Tips

Most cases of severe jaundice are preventable with early identification and proper care.

• Prenatal care: Screen mothers for blood type, Rh factor, and G6PD deficiency.
• Early post‑natal assessment: Check bilirubin levels before discharge (usually at 24 hours for term, 48 hours for preterm).
• Encourage effective breastfeeding:
  • Initiate within the first hour of life.
  • Ensure at least 8–12 feeds per 24 hours.
  • Seek lactation support if the baby is not gaining weight.
• Watch for early jaundice: If yellowing appears within the first 24 hours, contact a provider immediately.
• Maintain adequate hydration: For breast‑fed infants, consider supplemental formula or expressed milk if intake is low.
• Avoid medications that displace bilirubin: Discuss any maternal or infant drug use with the pediatrician.
• Follow discharge instructions: Many hospitals provide a bilirubin risk chart and a follow‑up appointment within 48 hours.
• Educate caregivers: Teach how to recognize worsening jaundice and when to seek care.

Emergency Warning Signs

---

**References**

• Mayo Clinic. “Neonatal Jaundice.” https://www.mayoclinic.org
• American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” *Pediatrics* 2022; 150(4):e2022058645.
• World Health Organization. “Guidelines on the Management of Neonatal Jaundice.” WHO, 2020.
• Cleveland Clinic. “Kernicterus – Symptoms, Causes, and Treatment.” https://my.clevelandclinic.org
• National Institutes of Health. “G6PD Deficiency.” NIH Genetics Home Reference, 2021.
• Centers for Disease Control and Prevention. “Neonatal Jaundice.” CDC, 2023.

```